Evidence map›Paper›PMID 32993631›Full record

ArticleBMC endocrine disorders2020

Extraordinarily long-inactive solitary fibrous tumor transformed to produce big insulin-like growth factor-2, leading to hypoglycemia and rapid liposarcoma growth: a case report.

Keizo Kaneko, Shojiro Sawada, Chihiro Satake, Keiichi Kondo, Tomohito Izumi, Mamiko Tanaka, Junta Imai, Tetsuya Yamada, Hiroki Katsushima, Fumiyoshi Fujishima and 1 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC endocrine disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. [Doege-Potter syndrome and intra-abdominal giant solitary fibrous tumor: Case report].Revista medica del Instituto Mexicano del Seguro Social · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Keizo KanekoDepartment of Diabetes and Metabolism, Tohoku University Hospital, 2-1 Seiryo, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Shojiro SawadaDepartment of Diabetes and Metabolism, Tohoku University Hospital, 2-1 Seiryo, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Chihiro SatakeDepartment of Diabetes and Metabolism, Tohoku University Hospital, 2-1 Seiryo, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Keiichi KondoDepartment of Diabetes and Metabolism, Tohoku University Hospital, 2-1 Seiryo, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Tomohito IzumiDepartment of Diabetes and Metabolism, Tohoku University Hospital, 2-1 Seiryo, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Mamiko TanakaDepartment of Diabetes and Metabolism, Tohoku University Hospital, 2-1 Seiryo, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Junta ImaiDepartment of Diabetes and Metabolism, Tohoku University Hospital, 2-1 Seiryo, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Tetsuya YamadaDepartment of Diabetes and Metabolism, Tohoku University Hospital, 2-1 Seiryo, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Hiroki KatsushimaDivision of Hematopathology, Tohoku University Hospital, Sendai, Aoba-ku, Japan.
Fumiyoshi FujishimaDivision of Hematopathology, Tohoku University Hospital, Sendai, Aoba-ku, Japan.
Hideki KatagiriDepartment of Diabetes and Metabolism, Tohoku University Hospital, 2-1 Seiryo, Aoba-ku, Sendai, Miyagi, 980-8575, Japan. katagiri@med.tohoku.ac.jp.
Tohoku University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA high-molecular-weight form of insulin-like growth factor-2 (IGF-2), known as "big" IGF-2, is occasionally produced by various tumor types, leading to hypoglycemia. Although solitary fibrous tumor (SFT) is a rare mesenchymal neoplasm, it has been estimated that 4-6% of SFT patients develop hypoglycemia due to circulating big IGF-2. The mean time elapsed from tumor detection until the onset of hypoglycemia is reportedly less than one year (8.5 ± 1.9 months). CASE PRESENTATION: A 68-year-old man was hospitalized for exacerbation of recurring hypoglycemic episodes. He had been diagnosed with an SFT 17 years before the onset of hypoglycemia, and the SFT had already been very large at that time. The tumor, which was non-resectable and refractory to chemotherapies, had slowly increased in size since the initial diagnosis. Half a year before the hypoglycemic episodes manifested, another tumor, adjacent to the left kidney, was newly identified. Fluorodeoxyglucose positron emission tomography-computed tomography scanning, revealed the left peri-renal tumor to show much higher fluorodeoxyglucose uptake than the preexisting SFT, suggesting that it was unlikely to be a metastasis from the SFT. Abundant serum big IGF-2 was detected by western immunoblot analysis, indicating it to be the cause of the hypoglycemia. Since the 17 years between SFT detection and the onset of IGF-2-induced hypoglycemia was an extremely long period as compared with those in previous reports, we initially suspected that the new, peri-renal tumor had produced big IGF-2, but transcatheter arterial embolization of its feeding arteries did not suppress hypoglycemia. Notably, by measuring the tumor volume doubling time, the peri-renal tumor growth was shown to be markedly accelerated in parallel with exacerbation of the hypoglycemia. The patient died of heart failure 21 months after the onset of hypoglycemia. Unexpectedly, autopsy revealed that big IGF-2 had been produced only by the preexisting SFT, not the peri-renal tumor, and that the peri-renal tumor was a dedifferentiated liposarcoma.

conclusionsWe should keep in mind that even a long-inactive SFT can undergo transformation to produce big IGF-2, which then acts on both insulin and IGF-1 receptors, possibly leading to both hypoglycemia and the development/growth of another tumor, respectively.

Indexed as

AgedHumansHypoglycemiaInsulin-Like Growth Factor IILiposarcomaMalePrognosisSolitary Fibrous TumorsIGF2 protein, humanInsulin-Like Growth Factor IICase reportHypoglycemiaInsulin-like growth factor-2Solitary fibrous tumorTumor growth

Identifiers

PMID32993631
PMCPMC7526150
OpenAlexW3089845642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.